Arotinolol (BioDeep_00000015213)
代谢物信息卡片
化学式: C15H21N3O2S3 (371.07958460000003)
中文名称: 阿罗洛尔
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)(C)NCC(CSC1=NC(=CS1)C2=CC=C(S2)C(=O)N)O
InChI: InChI=1S/C15H21N3O2S3/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20)
描述信息
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker[1]. Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites[2]. Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases[1].
同义名列表
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:135569
- KEGG: C76165
- KEGGdrug: D07465
- PubChem: 2239
- DrugBank: DB09204
- ChEMBL: CHEMBL93298
- CAS: 68377-92-4
- medchemexpress: HY-122537A
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Zheyuan Qian, Jian Le, Xiujuan Chen, Shengni Li, Hongjie Song, Zhanying Hong. High-throughput LC-MS/MS method with 96-well plate precipitation for the determination of arotinolol and amlodipine in a small volume of rat plasma: Application to a pharmacokinetic interaction study.
Journal of separation science.
2018 Feb; 41(3):618-629. doi:
10.1002/jssc.201700784. [PMID: 29115741] - Zheyuan Qian, Yanhai Xu, Leyi Zheng, Jingbo Zhang, Zhanying Hong, Xiaohang Shen. Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis.
2015 Jan; 102(?):299-304. doi:
10.1016/j.jpba.2014.09.034. [PMID: 25459927] - H Abdine, M A Sultan, M M Hefnawy, F Belal. Spectrofluorometric determination of some beta-blockers in tablets and human plasma using 9,10-dimethoxyanthracene-2-sodium sulfonate.
Die Pharmazie.
2005 Apr; 60(4):265-8. doi:
NULL. [PMID: 15881605] - Hassan Y Aboul-Enein, Mohamed M Hefnawy. Enantioselective determination of arotinolol in human plasma by HPLC using teicoplanin chiral stationary phase.
Biomedical chromatography : BMC.
2003 Oct; 17(7):453-7. doi:
10.1002/bmc.271. [PMID: 14598329] - Mohammed M Hefnawy. Micellar electrokinetic capillary chromatography determination of +S and -R arotinolol in serum using UV detection and solid phase extraction.
Chirality.
2002 Jan; 14(1):67-71. doi:
10.1002/chir.888. [PMID: 11748803] - H Suzuki, K Moriwaki, Y Kanno, H Nakamoto, H Okada, X M Chen. Comparison of the effects of an ACE inhibitor and alphabeta blocker on the progression of renal failure with left ventricular hypertrophy: preliminary report.
Hypertension research : official journal of the Japanese Society of Hypertension.
2001 Mar; 24(2):153-8. doi:
10.1291/hypres.24.153. [PMID: 11325074] - H Suzuki, H Nakamoto, H Nemoto, S Sugahara, H Okada. Control of blood pressure and prevention of end-organ damage in patients with accelerated hypertension by combination with arotinolol and extended release nifedipine.
Hypertension research : official journal of the Japanese Society of Hypertension.
2000 Mar; 23(2):159-66. doi:
10.1291/hypres.23.159. [PMID: 10770263] - E Miyauchi, M Matsumoto, Y Kimura, H Hattori, Y Tsukio, H Tsuchiya, M Takasaki, J Munehira, K Yamada, K Iwai, K Kawanishi, T Hoshino, H Murai. [Clinical effect of arotinolol hydrochloride and its influence on renal function in elderly patients with essential hypertension].
Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.
1999 Aug; 36(8):542-6. doi:
10.3143/geriatrics.36.542. [PMID: 10554561] - H Nakamoto, H Nemoto, S Sugahara, H Okada, H Suzuki. Nifedipine and arotinolol in combination for accelerated-malignant hypertension: results of one year follow-up.
Hypertension research : official journal of the Japanese Society of Hypertension.
1999 Jul; 22(2):75-80. doi:
10.1291/hypres.22.75. [PMID: 10487322] - S Ohguni, K Notsu, J Tanaka, T Sato, Y Kato. [Effect of arotinolol on insulin secretion and insulin clearance rate in patients with Graves' disease].
Nihon Naibunpi Gakkai zasshi.
1993 Aug; 69(7):650-8. doi:
10.1507/endocrine1927.69.7_650. [PMID: 7690718] - T Shiigai. Effects of long-term therapy with arotinolol on blood pressure and renal function in hypertensive patients with chronic renal failure.
Clinical therapeutics.
1993 Mar; 15(2):330-7. doi:
NULL. [PMID: 7686085] - N Fukasawa, M Iitaka, S Kitahama, S Miura, S Sakurai, Y Kawakami, J Ishii. [The effect of arotinolol on the thyroid function and the autonomic nerve systems].
Nihon Naibunpi Gakkai zasshi.
1993 Jan; 69(1):25-32. doi:
10.1507/endocrine1927.69.1_25. [PMID: 7680618] - T Mori, K Handa, Y Terao, H Tanaka, A Kiyonaga, M Shindo, A Matsunaga, J Sasaki, K Arakawa. Effects of arotinolol on exercise capacity and humoral factors during exercise in normal subjects.
Cardiovascular drugs and therapy.
1992 Aug; 6(4):387-90. doi:
10.1007/bf00054186. [PMID: 1381611] - K Asayama, H Hayashibe, K Dobashi, K Kato. Differential effects of 3 beta blockers on lipid peroxidation in hyperthyroid muscle.
Endocrinologia japonica.
1990 Aug; 37(4):471-8. doi:
10.1507/endocrj1954.37.471. [PMID: 1707360] - J Sasaki, K Handa, K Arakawa. Effects of arotinolol on serum lipid and apolipoprotein levels in patients with mild essential hypertension.
Clinical therapeutics.
1989 Sep; 11(5):580-3. doi:
NULL. [PMID: 2478285] - J Yamamoto, H Matsubara, M Nakai. Effect of arotinolol on hemodynamics and plasma atrial natriuretic peptide at rest and during stress in spontaneously hypertensive rats.
Clinical and experimental hypertension. Part A, Theory and practice.
1989; 11(8):1441-54. doi:
10.3109/10641968909038175. [PMID: 2482144] - M Suzuki-Kusaba, H Hisa, T Kimura, S Satoh. Effects of arotinolol on hemodynamics and adrenergically induced renin release and renal vasoconstriction.
Arzneimittel-Forschung.
1988 May; 38(5):671-7. doi:
NULL. [PMID: 2458109] - S Morimoto, N Miyawaki, Y Sasaki, Y Matsumura. Effects of arotinolol, an alpha- and beta-adrenoceptor antagonist, on renin release from rat kidney cortical slices.
Clinical and experimental pharmacology & physiology.
1986 Jun; 13(6):505-10. doi:
10.1111/j.1440-1681.1986.tb00931.x. [PMID: 2428551] - H Nakahara, M Nakazawa, T Tsukada, S Imai. Mechanism of the hypotensive effect of a new beta-adrenergic blocking drug, arotinolol (S-596) in anesthetized rabbits.
Archives internationales de pharmacodynamie et de therapie.
1985 Oct; 277(2):253-63. doi:
NULL. [PMID: 2415080] - K Kishi, K Kawashima, H Sokabe, K Saito. Chronic effects of arotinolol (S-596) in spontaneously hypertensive rats.
Journal of pharmacobio-dynamics.
1985 Jan; 8(1):50-5. doi:
10.1248/bpb1978.8.50. [PMID: 2409263] - M Nakashima, T Uematsu, Y Takiguchi, H Hashimoto, I Watanabe, S Morioka, T Hibino. Effect of ophthalmic administration of S-596 (Arotinolol) on intraocular pressure and haemodynamics in health volunteers: comparison with timolol.
European journal of clinical pharmacology.
1985; 28(4):391-6. doi:
10.1007/bf00544356. [PMID: 2411566]